Mayumi Nakagawa, MD, PhD awarded $3.6 million to expand HPV cancer vaccine study

Mayumi Nakagawa, MD, PhD

Mayumi Nakagawa, MD, PhD, was awarded $3.6 million from the National Cancer Institute (NCI) to complete phase 2 clinical trials of PepCan, a breakthrough vaccine she developed at the University of Arkansas for Medical Sciences (UMAS) to treat cancers caused by human papillomavirus (HPV).

An internationally recognized expert in HPV immunology, Nakagawa is the Drs. Mae and Anderson Nettleship Endowed Chair in Oncologic Pathology and a professor of Pathology and Laboratory Sciences in the UAMS College of Medicine. She is co-leader of the Cancer Prevention and Population Sciences Program in the UAMS Winthrop P. Rockefeller Cancer Institute.

The Centers for Disease Control report that HPV is responsible for more than 90% of anal and cervical cancers, about 70% of vaginal and vulvar cancers, and more than 60% of penile cancers.

While most HPV vaccines prevent the virus in people who have never had it, Nakagawa’s vaccine shows promise in treating women who already have HPV and are more likely to get cancer.

She has continuously received outside funding from numerous organizations such as the Cancer Research Institute, the American Cancer Society, and the NCI of the National Institutes of Health (NIH).

Dr. Nakagawa serves on various NIH study sections including those evaluating applications under standard mechanisms such as R01s and R21s, as well as applications under other mechanisms such as Specialized Programs for Research Excellence, Human Immunology Project Consortium, and NIH Director’s Pioneer Award.

Read more here.

#ASIP2022 at #ExpBio Abstract Submission Site Opens soon!


Build your national reputation by reconnecting with colleagues, and meeting new scientists who provide outstanding research and cutting-edge advances in the biomedical science field.

Experience new opportunities and learn how the ASIP enhances its strong commitment to supporting scientists at all career levels. Members who submit abstracts are eligible to be considered for awards which will cover registration costs.

The abstract submission site will open on September 15, 2021 which is less than a month away!

There is a place for your science when you submit your current research to an ASIP topic category. International scientists who require a visa to attend the Experimental Biology meeting should take advantage of this opportunity and get a jump on the visa application process. 

Thank you for your participation. We look forward to receiving a record number of abstracts and highlighting the science represented by our diverse membership.

Why Attend?

  • Present your research during a symposia, lecture, or poster talk
  • Extend your research knowledge by attending cutting-edge scientific sessions and abstract-driven minisymposia
  • Attend award lectures and educational sessions
  • Interact in networking events for your specialty
  • Receive travel and scholar Awards
  • Collaborate with 5 Host societies meetings in a single location with one registration fee
  • Learn from presentations by keynote speakers
  • Gain experience from oral presentations on cutting-edge science
  • Orchestrate professional development skills
  • Get published in the FASEB Journal
  • Network with >12,000 scientists in attendance
  • Take part in more than 50 concurrent scientific sessions featuring the latest in biomedical research
  • Meet representatives from over 300 exhibitors
  • See over 5,000 poster presentations
  • Get noticed by a diverse audience with over 65 countries represented
  • Receive tips in the Career Center

We look forward to seeing you and your science at EB 2022 in Philadelphia, PA!

#MoreThanMembership | #YouBelongInASIP

Join me for #ASIP2022 at #ExpBio!